Influence of ghrelin gene polymorphisms on hypertension and atherosclerotic disease

Hypertension Research

Volumn 33, Issue 2, 2010, Pages 155-160

  Berthold, Heiner K ^a   Giannakidou, Eleni ^a,b   Krone, Wilhelm ^b   Trégouët, David Alexandre ^c   Gouni Berthold, Ioanna ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c INSERM   (France)

Author keywords

Ghrelin; Haplotype analysis; Polymorphism

Indexed keywords

GHRELIN; GLUCOSE; LIPOPROTEIN;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FEMALE; GHRELIN; HAPLOTYPES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 76349105010     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.194     Document Type: Article

References (27)

1. Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
2. van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophy-siological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-457.
3. Wiedmer P, Nogueiras R, Broglio F, D'Alessio D, Tschop MH. Ghrelin, obesity and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 705-712.
4. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C, Weintraub NL. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 2004; 109: 2221-2226.
5. Sharma V, McNeill JH. The emerging roles of leptin and ghrelin in cardiovascular physiology and pathophysiology. Curr Vasc Pharmacol 2005; 3: 169-180.
6. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, Cardillo C. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112: 2986-2992.
7. Katugampola SD, Pallikaros Z, Davenport AP. 125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol 2001; 134: 143-149.
8. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-2553.
9. Poykko SM, Kellokoski E, Ukkola O, Kauma H, Paivansalo M, Kesaniemi YA, Horkko S. Plasma ghrelin concentrations are positively associated with carotid artery atherosclerosis in males. J Intern Med 2006; 260: 43-52.
10. Mager U, Kolehmainen M, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto JO, Pulkkinen L, Uusitupa MI. Association between ghrelin gene variations and blood pressure in subjects with impaired glucose tolerance. Am J Hypertens 2006; 19: 920-926.
11. Poykko S, Ukkola O, Kauma H, Savolainen MJ, Kesaniemi YA. Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects. Diabetologia 2003; 46: 455-458.
12. Ukkola O, Kesaniemi YA. Preproghrelin Leu72Met polymorphism in patients with type 2 diabetes mellitus. J Intern Med 2003; 254: 391-394.
13. Tang NP, Wang LS, Yang L, Gu HJ, Zhu HJ, Zhou B, Sun QM, Cong RH, Wang B. Preproghrelin Leu72Met polymorphism in Chinese subjects with coronary artery disease and controls. Clin Chim Acta 2008; 387: 42-47. (Pubitemid 350050926)
14. Gouni-Berthold I, Giannakidou E, Müller-Wieland D, Faust M, Kotzka J, Berthold HK, Krone W. Association between the PPARalpha L162V polymorphism, plasma lipopro-tein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am Heart J 2004; 147: 1117-1124.
15. Gouni-Berthold I, Giannakidou E, Müller-Wieland D, Faust M, Kotzka J, Berthold HK, Krone W. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. J Hypertens 2005; 23: 301-308.
16. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 1038-1039.
17. Vouyouka AG, Kent KC. Arterial vascular disease in women. J Vasc Surg 2007; 46: 1295-1302.
18. Böger RH, Skamira C, Bode-Böger SM, Brabant G, von zur Mühlen A, Frölich JC. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest 1996; 98: 2706-2713.
19. Kim SY, Jo DS, Hwang PH, Park JH, Park SK, Yi HK, Lee DY. Preproghrelin Leu72Met polymorphism is not associated with type 2 diabetes mellitus. Metabolism 2006; 55: 366-370.
20. Mager U, Lindi V, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Laakso M, Pulkkinen L, Uusitupa M. Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study. Diabet Med 2006; 23: 685-689.
21. Bing C, Ambye L, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA. Large-scale studies of the Leu72Met polymorphism of the ghrelin gene in relation to the metabolic syndrome and associated quantitative traits. Diabet Med 2005; 22: 1157-1160.
22. Ukkola O, Ravussin E, Jacobson P, Perusse L, Rankinen T, Tschop M, Heiman ML, Leon AS, Rao DC, Skinner JS, Wilmore JH, Sjostrom L, Bouchard C. Role of ghrelin polymorphisms in obesity based on three different studies. Obes Res 2002; 10: 782-791.
23. Robitaille J, Perusse L, Bouchard C, Vohl MC. Genes, fat intake, and cardiovascular disease risk factors in the Quebec Family Study. Obesity (Silver Spring) 2007; 15: 2336-2347. (Pubitemid 350004102)
24. Kilpelainen TO, Lakka TA, Laaksonen DE, Mager U, Salopuro T, Kubaszek A, Todorova B, Laukkanen O, Lindstrom J, Eriksson JG, Hamalainen H, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M. Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome: The Finnish Diabetes Prevention Study. Metabolism 2008; 57: 428-436.
25. Mager U, Kolehmainen M, de Mello VD, Schwab U, Laaksonen DE, Rauramaa R, Gylling H, Atalay M, Pulkkinen L, Uusitupa M. Expression of ghrelin gene in peripheral blood mononuclear cells and plasma ghrelin concentrations in patients with metabolic syndrome. Eur J Endocrinol 2008; 158: 499-510.
26. Berthold HK, Giannakidou E, Krone W, Mantzoros CS, Gouni-Berthold I. The Leu72Met polymorphism of the ghrelin gene is associated with a decreased risk for type 2 diabetes. Clin Chim Acta 2009; 399: 112-116.
27. Baessler A, Kwitek AE, Fischer M, Koehler M, Reinhard W, Erdmann J, Riegger G, Doering A, Schunkert H, Hengstenberg C. Association of the Ghrelin receptor gene region with left ventricular hypertrophy in the general population: results of the MONICA/ KORA Augsburg Echocardiographic Substudy. Hypertension 2006; 47: 920-927. (Pubitemid 44297564)